Prostatic Artery Embolization Before Radical Prostatectomy in Prostate Cancer: A Proof-of-concept Study
NCT ID: NCT02917161
Last Updated: 2017-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2016-09-30
2017-08-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This proof of concept study assess the impact of PAE in patients with proven prostate cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prostatic Artery Embolization in Advanced Prostate Cancer
NCT03457805
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
NCT04879940
Phase II Investigation of Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients
NCT02173522
Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
NCT05415696
Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases
NCT02454543
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This proof of concept study assess the impact of PAE in patients with proven prostate cancer.
PAE is performed in patients that are planned to undergo robot-assisted laparoscopic prostatectomy for proven localized prostate cancer.
The impact of neo-adjuvantly performed PAE on histological tumor regression, surgical margins as well as on safety parameters are assessed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prostatic Artery Embolization (PAE)
PAE is performed 6weeks before RALP
Prostatic Artery Embolization (PAE)
PAE is performed 6 weeks before radical prostatectomy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prostatic Artery Embolization (PAE)
PAE is performed 6 weeks before radical prostatectomy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has biopsy-proven prostate adenocarcinoma
* Localized disease (tumorstage cT1-cT2), assessed by clinical and MRI findings
* Written informed consent
Exclusion Criteria
* Severe tortuosity or ectasia in the aortic bifurcation or internal iliac arteries
* Tumor stage \> cT2 assessed by clinical and MRI findings
* Allergy to intravenous contrast media
* Contraindication for MRI imaging
* Renal failure (GFR\<60ml/min)
* History of pelvic irradiation or radical pelvic surgery
45 Years
75 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dominik Abt
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dominik Abt
Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dominik Abt, MD
Role: PRINCIPAL_INVESTIGATOR
Cantonal Hospital St. Gallen
Livio Mordasini, MD
Role: PRINCIPAL_INVESTIGATOR
Cantonal Hospital Luzerne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cantonal Hospital Lucerne, Department of Urology
Lucerne, , Switzerland
Urological Department, Cantonal Hospital of St. Gallen
Sankt Gallen, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTU 15/015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.